A
Alex Kantor
Researcher at Columbia University
Publications - 10
Citations - 399
Alex Kantor is an academic researcher from Columbia University. The author has contributed to research in topics: Randomized controlled trial & Tricuspid valve. The author has an hindex of 7, co-authored 10 publications receiving 184 citations. Previous affiliations of Alex Kantor include Columbia University Medical Center.
Papers
More filters
Journal ArticleDOI
A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19.
Max R. O'Donnell,Beatriz Grinsztejn,Matthew J. Cummings,Jessica Justman,Matthew R. Lamb,Christina M. Eckhardt,Neena M. Philip,Ying Kuen Cheung,Vinay Gupta,Esau Joao,José Henrique Pilotto,Maria Pia Diniz,Sandra W. Cardoso,Darryl Abrams,Kartik N. Rajagopalan,Sarah Borden,Allison Wolf,Leon Claude Sidi,Alexandre Gomes Vizzoni,Valdilea G. Veloso,Zachary C. Bitan,Dawn E. Scotto,Benjamin J. Meyer,Samuel D. Jacobson,Alex Kantor,Nischay Mishra,Lokendra V. Chauhan,Elizabeth F. Stone,Flavia Dei Zotti,Francesca La Carpia,Krystalyn E. Hudson,Stephen A. Ferrara,Joseph E. Schwartz,Brie A. Stotler,Wen-Hsuan W. Lin,Sandeep N. Wontakal,Beth H. Shaz,Thomas Briese,Eldad A. Hod,Steven L. Spitalnik,Andrew Eisenberger,Walter Ian Lipkin +41 more
TL;DR: In a randomized, double-blind, controlled trial among adults hospitalized with severe and critical COVID-19 at 5 sites in New York City (USA) and Rio de Janeiro (Brazil), patients were randomized 2:1 to receive either convalescent plasma or normal control plasma as discussed by the authors.
Posted ContentDOI
A randomized, double-blind, controlled trial of convalescent plasma in adults with severe COVID-19
Max R. O'Donnell,Beatriz Grinsztejn,Matthew J. Cummings,Jessica Justman,Matt Lamb,Christina M. Eckhardt,Neena Phillip,Kenneth Cheung,Darryl Abrams,Vinay Gupta,Maria Pia Diniz,Sandra W. Cardoso,Kartik N. Rajagopalan,Sarah Borden,Allison Wolf,Zachary C. Bitan,Benjamin J. Meyer,Samuel G. Jacobson,Alex Kantor,Nischay Mishra,Eldad A. Hod,Thomas Briese,Leon Claude Sidi,Sandeep N. Wontakal,Krystalyn E. Hudson,Brie A. Stotler,Wen-Hsuan W. Lin,José Henrique Pilotto,Esau Joao,Lokendra V. Chauhan,Valdilea G. Veloso,Joseph E. Schwartz,Elizabeth F. Stone,Flavia Dei Zotti,Francesca La Carpia,Beth H. Shaz,Stephen A. Ferrara,Alexandre Gomes Vizzoni,Steven Spitalnick,Andrew Eisenberger,W. Ian Lipin +40 more
TL;DR: In this paper, the clinical efficacy and safety of convalescent plasma among adults hospitalized with severe and critical COVID-19 was evaluated in a randomized controlled trial conducted from April 21st to November 27th, 2020.
Journal ArticleDOI
Early Single-Site Experience With Transcatheter Tricuspid Valve Replacement.
Rebecca T. Hahn,Isaac George,Susheel Kodali,Tamim Nazif,Omar K. Khalique,Deniz Akkoc,Alex Kantor,Torsten Vahl,Amisha Patel,Elliott Elias,Vivian Ng,Roberto Spina,Krzysztof Bartus,Poonam Velagapudi,Isaac Y. Wu,Martin B. Leon,Vinayak Bapat +16 more
TL;DR: Implantation of a first-generation TTVR device was technically feasible in patients with more than severe TR andTranscatheter tricuspid valve replacement was associated with RV remodeling, increased cardiac output, and improvement in New York Heart Association functional class in most patients.
Journal ArticleDOI
Cardiac Donor Risk Factors Predictive of Short-Term Heart Transplant Recipient Mortality: An Analysis of the United Network for Organ Sharing Database.
Robert Sorabella,Laura Guglielmetti,Alex Kantor,Estibaliz Castillero,Hiroo Takayama,Paul Christian Schulze,Donna Mancini,Yoshifumi Naka,Isaac George +8 more
TL;DR: The data suggest that donors who are older, female, or have a long projected ischemic time pose greater risk to heart transplant recipients in the short term, and certain components of donor management protocols, including antihypertensive and insulin administration, may be protective to recipients.
Journal ArticleDOI
Correction to: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Christina M. Eckhardt,Matthew J. Cummings,Kartik N. Rajagopalan,Sarah Borden,Zachary C. Bitan,Allison Wolf,Alex Kantor,Thomas Briese,Benjamin J. Meyer,Samuel D. Jacobson,Dawn Scotto,N. Mishra,Neena M. Philip,Brie A. Stotler,Joseph E. Schwartz,Beth H. Shaz,Steven L. Spitalnik,Andrew Eisenberger,Eldad A. Hod,Jessica Justman,Ken Cheung,W. Ian Lipkin,Max R. O'Donnell +22 more
TL;DR: The primary endpoint is time to clinical improvement, which is defined as time from randomization to either discharge from the hospital or improvement by one point on the following seven-point ordinal scale, whichever occurs first.